BCR and lymphoma: In analogy to the above-mentioned carcinomas of the lung and prostate transdifferentiating in response to therapies targeting EGFR (31) and androgen (32) signaling, respectively, targeted therapies may be responsible for lymphoma reprogramming from the dependence on BCR signaling.